Pediatric Acute Respiratory Distress Syndrome (PARDS) is a life-threatening form of acute, non-cardiogenic, inflammatory pulmonary edema resulting in severe hypoxemic respiratory failure, reduced lung compliance, and increased physiological dead space. Following the landmark 2015 Pediatric Acute Lung Injury Consensus Conference (PALICC-1), significant clinical evidence and technological advances necessitated the comprehensive Second Pediatric Acute Lung Injury Consensus Conference (PALICC-2) updated recommendations in 2023.

PALICC-2 establishes refined diagnostic thresholds, introduces classifications for non-invasive respiratory support and patients "at risk," stratifies severity utilizing the mean airway pressure ($mPaw$)-weighted Oxygenation Index ($\text{OI}$) and Oxygen Saturation Index ($\text{OSI}$), and mandates strict lung-protective ventilation and evidence-based adjunctive protocols.

flowchart TD
    A["Suspected Acute Respiratory Deterioration in Pediatric Patient"] --> B{"Meets Core PALICC-2 Entry Criteria?<br/>• Age: Gestational age > 42 wks to 18 yrs<br/>• Timing: ≤ 7 days from clinical insult<br/>• Imaging: New parenchymal infiltrate(s)<br/>• Non-cardiogenic: Not fully explained by LV failure/fluid"}
    
    B -- "No" --> C["Manage Alternative Etiology (Congenital Heart Disease, Fluid Overload, Neuromuscular)"]
    B -- "Yes" --> D{"Current Respiratory Support Modality"}
    
    D -- "NIV / CPAP ≥ 5 cmH2O or HFNC" --> E{"Oxygenation Impairment"}
    E -- "CPAP/BiPAP: P/F ≤ 300 or S/F ≤ 264" --> F["Non-Invasive PARDS"]
    E -- "HFNC (Age-based flow) & FiO2 ≥ 0.40" --> G["At-Risk for PARDS"]
    
    D -- "Invasive Mechanical Ventilation (PEEP ≥ 5 cmH2O)" --> H{"Calculate Oxygenation Metric<br/>(OI or OSI when SpO2 ≤ 97%)"}
    
    H -- "4.0 ≤ OI < 8.0  OR  5.0 ≤ OSI < 7.5" --> I["Mild Invasive PARDS"]
    H -- "8.0 ≤ OI < 16.0  OR  7.5 ≤ OSI < 12.3" --> J["Moderate Invasive PARDS"]
    H -- "OI ≥ 16.0  OR  OSI ≥ 12.3" --> K["Severe Invasive PARDS"]
    
    F --> L["Time-Limited NIV Trial (1-2 h)<br/>• Monitor work of breathing & p-ROXI<br/>• Rapid escalation if failing"]
    I --> M["Standard Lung-Protective Ventilation<br/>• Vt 5-8 mL/kg; Pplat ≤ 28; ΔP ≤ 15<br/>• Titrate PEEP: 8-10 cmH2O"]
    J --> N["Optimized Protective Strategy<br/>• Vt 4-6 mL/kg; PEEP 10-15 cmH2O<br/>• Target SpO2 88-92%; Early Cisatracurium"]
    K --> O["Refractory Escalation Ladder<br/>• Deep Sedation + NMBA (≤ 48 h)<br/>• Prone Positioning (≥ 16 h/day)<br/>• Inhaled NO Rescue (10-20 ppm)<br/>• Evaluate for VV-ECMO (OI ≥ 40 or refractory)"]

PALICC-2 Consensus Definition & Diagnostic Framework

The PALICC-2 definition standardizes pediatric lung injury diagnosis across heterogeneous international clinical settings, accounting for anatomical variations, variable arterial blood gas availability, and the rising utilization of non-invasive modalities.

Non-Invasive vs. Invasive PARDS Criteria

PALICC-2 established clear bifurcations between non-invasive support, invasively ventilated patients, and vulnerable children categorized as "At-Risk":

Oxygenation Metrics & Severity Stratification

In adult ARDS (Berlin definition), severity is stratified by the $PaO_2/FiO_2$ ratio without incorporating the distending airway pressure. In pediatric critical care, mean airway pressure ($mPaw$) varies markedly depending on endotracheal tube size, chest wall elastance, and clinician ventilator strategy. PALICC-2 mandates the Oxygenation Index ($\text{OI}$) as the primary stratification metric and the Oxygen Saturation Index ($\text{OSI}$) as the primary non-invasive surrogate.

flowchart LR
    subgraph Invasive_Severity["Invasive PARDS Severity Stratification"]
        direction TB
        MILD["Mild PARDS<br/>4.0 ≤ OI < 8.0<br/>5.0 ≤ OSI < 7.5"]
        MOD["Moderate PARDS<br/>8.0 ≤ OI < 16.0<br/>7.5 ≤ OSI < 12.3"]
        SEV["Severe PARDS<br/>OI ≥ 16.0<br/>OSI ≥ 12.3"]
        MILD --> MOD --> SEV
    end

PALICC-2 Invasive Severity Classification Matrix

PALICC-2 Lung-Protective Mechanical Ventilation Strategy

The primary goal of invasive mechanical ventilation in PARDS is maintaining adequate gas exchange while preventing Ventilator-Induced Lung Injury (VILI)—specifically barotrauma, volutrauma, atelectrauma, and biotrauma.

Figure 1: Pathophysiological mechanisms of cyclic alveolar collapse and shear stress (atelectrauma) with low PEEP versus alveolar stabilization and recruitment with adequate PEEP in heterogeneous lung injury and Pediatric Acute Respiratory Distress Syndrome (PARDS). Sourced from Allen et al., Translational Pediatrics 2026; DOI: 10.21037/tp-2025-aw-684 .

Tidal Volume ($V_t$) Titration & Baby Lung Concept

In PARDS, the functional aerated lung volume (the "baby lung") is drastically reduced due to inflammatory consolidation and atelectasis. Standardizing tidal volumes to ideal body weight rather than actual weight is imperative to prevent regional overdistension.

• Standard Starting Target: $5 - 8\text{ mL/kg}$ predicted body weight (PBW).
• Poorly Compliant / Severe Lungs: Reduce to $3 - 6\text{ mL/kg}$ PBW when respiratory system compliance ($C_{rs}$) is severely diminished or plateau pressures exceed safe thresholds.

Driving Pressure ($\Delta P$) and Plateau Pressure ($P_{plat}$) Limits

PEEP Titration and Open Lung Physiology

Positive End-Expiratory Pressure must be set to prevent end-expiratory alveolar collapse, recruit unstable alveolar units, restore Functional Residual Capacity (FRC), and reduce regional shear stress without inducing capillary compression or RV afterload elevation.

PALICC-2 recommends titrating PEEP according to validated pediatric PEEP/FiO2 titration grids while actively assessing bedside compliance and hemodynamics:

Gas Exchange & Permissive Hypercapnia Targets

• Oxygenation Targets:
  • On Low PEEP ($< 10\text{ cmH}_2\text{O}$): Target $SpO_2 92 - 97\%$.
  • On High PEEP ($\ge 10\text{ cmH}_2\text{O}$): Accept permissive hypoxemia targeting $SpO_2 88 - 92\%$ to avoid lethal oxygen toxicity and excessive airway pressures.
• Permissive Hypercapnia:
  • Accept arterial $pH 7.20 - 7.25$ (and down to $7.15$ in refractory severe cases) to facilitate ultra-lung-protective low $V_t$ ventilation.
  • Contraindications: Acute intracranial hypertension, severe traumatic brain injury, acute severe pulmonary hypertension, severe metabolic acidosis, or uncompensated hemodynamic instability.

Stepwise Ventilatory Titration & Escalation Ladder

flowchart TD
    subgraph Ladder["PALICC-2 Stepwise Management Ladder"]
        STEP1["<b>Step 1: Baseline Lung Protection</b><br/>• Mode: PC-CMV or PRVC<br/>• Vt: 5-8 mL/kg PBW (titrate to 3-6 if Crs low)<br/>• Target Pplat ≤ 28 cmH2O, ΔP ≤ 15 cmH2O<br/>• PEEP titration via PEEP/FiO2 scale"]
        
        STEP2["<b>Step 2: Moderate PARDS Optimization (OI 8-16)</b><br/>• Increase PEEP (10-15 cmH2O)<br/>• Permissive hypercapnia (pH ≥ 7.20)<br/>• Target SpO2 88-92%<br/>• Early targeted Neuromuscular Blockade (Cisatracurium)"]
        
        STEP3["<b>Step 3: Severe PARDS Rescue (OI ≥ 16)</b><br/>• Prone Positioning (≥ 16 h/day)<br/>• Deep sedation + continuous NMBA (≤ 48 h)<br/>• Inhaled Nitric Oxide (iNO 10-20 ppm) for acute RV dysfunction/refractory hypoxemia<br/>• Recruitment maneuvers (slow incremental PEEP staircase)"]
        
        STEP4["<b>Step 4: Refractory PARDS & Extracorporeal Support</b><br/>• High-Frequency Oscillatory Ventilation (HFOV rescue)<br/>• Veno-Venous (VV) ECMO Evaluation (OI ≥ 40 or refractory hypercapnia with pH < 7.15)"]
        
        STEP1 --> STEP2 --> STEP3 --> STEP4
    end

Evidence-Based Adjuvant Therapies

flowchart LR
    A["Severe PARDS (OI ≥ 16)"] --> B["Prone Positioning<br/>≥ 16 h/day"]
    A --> C["Early NMBA<br/>Continuous ≤ 48 h"]
    A --> D["Inhaled NO<br/>Rescue: 10-20 ppm"]
    A --> E["Surfactant Therapy<br/>NOT Routinely Recommended"]
    A --> F["Extracorporeal Life Support<br/>VV vs VA ECMO"]

1. Prone Positioning

• Mechanism: Re-distributes transpulmonary pressure gradients, promotes dorsal alveolar recruitment, improves ventilation-perfusion matching, and reduces dorsal alveolar strain.
• PALICC-2 Recommendation: Strongly recommended for severe PARDS ($\text{OI} \ge 16$ or $\text{OSI} \ge 12.3$).
• Dosage / Duration: Minimum of $16 - 24\text{ hours/day}$ in continuous sessions until significant sustained oxygenation improvement occurs.

2. Neuromuscular Blockade (NMBA)

• Mechanism: Eliminates patient-ventilator asynchrony, reduces oxygen consumption, prevents reverse triggering and pendelluft phenomenon, and controls transpulmonary pressure spikes.
• PALICC-2 Recommendation: Early targeted continuous infusion of non-depolarizing NMBA (e.g., cisatracurium) is recommended for moderate-to-severe PARDS for a duration of $\le 48\text{ hours}$. Routine prolonged paralysis beyond 48 hours is discouraged due to ICU-acquired weakness and myopathy.

3. Inhaled Pulmonary Vasodilators (iNO & Prostacyclin)

• Mechanism: Inhaled nitric oxide (iNO, $5 - 20\text{ ppm}$) selectively dilates pulmonary vasculature in well-ventilated lung units, decreasing intrapulmonary shunt, reducing pulmonary vascular resistance (PVR), and unloading the right ventricle.
• PALICC-2 Recommendation: Not recommended routinely for all PARDS patients. Recommended as a rescue therapy in severe PARDS with documented acute pulmonary hypertension, severe acute cor pulmonale / RV failure, or refractory hypoxemia failing other strategies. Discontinue if no objective improvement occurs within 4–6 hours.

4. Exogenous Surfactant Therapy

• PALICC-2 Recommendation: Exogenous surfactant is not routinely recommended in pediatric patients with secondary PARDS (direct or indirect lung injury) due to a lack of demonstrable mortality benefit in large multicenter trials. May be considered selectively in specific primary surfactant deficiency phenotypes (e.g., severe neonatal transition or select tracheobronchial aspiration).

5. Extracorporeal Life Support (ECLS / ECMO)

Summary Protocol for Bedside PARDS Management

Key Takeaways

1. Continuous Metric Stratification: In invasively ventilated pediatric patients, always calculate the mean airway pressure-weighted Oxygenation Index ($\text{OI}$) or the pulse oximetry surrogate Oxygen Saturation Index ($\text{OSI}$) (when $SpO_2 \le 97\%$) rather than isolated $P/F$ ratios.
2. Driving Pressure Is Paramount: Titrate tidal volumes ($3-6\text{ mL/kg}$ PBW in severe PARDS) and PEEP to minimize driving pressure ($\Delta P \le 14-15\text{ cmH}_2\text{O}$) and maintain plateau pressure $P_{plat} \le 28\text{ cmH}_2\text{O}$.
3. Early Multimodal Rescue: In severe PARDS ($\text{OI} \ge 16$), initiate prone positioning ($\ge 16\text{ h/day}$) and early targeted neuromuscular blockade without delay.
4. Timely Extracorporeal Escalation: Initiate early consultation for VV-ECMO when $\text{OI} \ge 40$ or uncompensated hypercapnia persists, shifting the patient promptly to lung-rest ventilation.